An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tekla Life Sciences Investors Declares Distribution
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
On November 15, 2022, Tekla Life Sciences Investors announced a distribution of $0.31 per share. The record date is November 25, 2022, with payment on December 30, 2022. The fund will trade ex-distribution on November 23, 2022. Distributions will be based on 2% of the fund’s net assets, meaning amounts may vary. Shareholders can opt for cash instead of shares by responding through their brokers or via Computershare Investor Services before December 20, 2022. Tekla Life Sciences Investors invests in life sciences companies and is traded on the NYSE.
Positive
Distribution announced at $0.31 per share.
Consistent distribution policy at 2% of net assets.
Negative
Distributions can decrease if the fund's net assets decline.
BOSTON--(BUSINESS WIRE)--
On November 15, 2022, Tekla Life Sciences Investors declared a distribution of $0.31 per share. The record date for the distribution is November 25, 2022 and the payable date is December 30, 2022. The Fund will trade ex-distribution on November 23, 2022.
Under its distribution policy, the Fund intends to make quarterly distributions at a rate of 2% of the Fund’s net assets. Therefore, when the net assets of the Fund are down, the distribution per share amount will decrease and when the net assets are up, the distribution amount per share will increase. This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, December 21, 2022. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.
Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in “street name” or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company ("DTC") as to their full and fractional share requirements by December 20, 2022. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to December 20, 2022.
Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.
Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.
Please contact Destra Capital Advisors, the Fund’s marketing and investor support services agent, at HQL@destracapital.com or call (877) 855-3434 if you have any questions regarding HQL.
